Neuropeptide Galanin Increase ROS and IL-1β Production by Blood Cells from Patients with Multiple Sclerosis

Pedro Henrique Villar-Delfino, Caroline Maria Oliveira Volpe, Thais Cristina Miranda, Paulo Pereira Christo and Jose Augusto Nogueira-Machado

Abstract

Objective: Galanin (GAL), a neuropeptide produced in the central and peripheral nervous system, has been involved in the modulation of the inflammatory response. Our present study aimed to evaluate the effect of GAL on the production of reactive oxygen species (ROS) by granulocytes and the secretion of IL-1β by peripheral blood mononuclear cells (PBMC) from patients with Multiple Sclerosis (MS) and healthy control cells, comparatively.

Methods: Granulocytes and PBMC from patients with MS and healthy controls were purified simultaneously by the Ficoll-Hypaque gradient method. The effect of GAL on ROS generation by granulocytes was performed in a luminol-dependent chemiluminescence assay. The quantification of IL-1β in the supernatant of cultured-PBMC was determined using immunoassay (ELISA).

Results: Our results showed that ROS production in the presence of GAL was significantly higher (p<0.05) in granulocytes of MS patients than that observed in healthy control cells. GAL activated IL-1β secretion similarly in both PBMC of MS patients and healthy controls (p>0.05).

Conclusion: GAL modulates the production of ROS and activates inflammasome evaluated by the increase of IL-1β secretion and it may have consequences in the inflammatory process observed in MS.

Keywords: Multiple sclerosis; Galanin; Reactive oxygen species; IL-1β; Inflammasome; Inflammation; Innate immunity; Granulocytes; Mononuclear cells

Introduction

Multiple sclerosis (MS) is a neurodegenerative disease that affects the central (CNS) and peripheral (PNS) nervous system. Neuronal demyelination in the brain and spinal neurons is observed in MS leading to the total or partial interruption of nervous influx [1-3]. It is reported that the neuropeptide Galanin (GAL) is secreted mainly by oligodendrocytes, astrocytes and gastrointestinal apparatus protecting against demyelination and promoting myelination of the neuron [4,5]. Galanin (GAL) is a neuropeptide-containing a 29/30 amino acid and its biological action occur through interaction with three different receptors, GALR1, GALR2 and GALR3 [6-8] with main distribution in the CNS, PNS, and intestine [6,9]. Galanin is an immunomodulatory neuropeptide and act regulating several physiological processes, [6,10-14]. ROS and pro-inflammatory cytokines promote the migration of inflammatory cells (neutrophils, macrophages, lymphocytes) to the brain due to the increase of permeability of the blood-brain barrier (BBB) [2,3]. In pathological conditions such as MS, the increase in ROS production exceeds the physiological threshold, generating oxidative stress, an important factor associated with the development of demyelination [15-21]. Among proinflammatory cytokines, IL-1β plays a pivotal role in increasing the permeability of the BBB [22,23]. Its production depends on the inflammasome activation [24], a multiprotein complex of intracellular signalling, sensitive to oxidative stress. Inflammasome induces the maturation and secretion of IL-1β and IL-18 through the activation of caspase-1 besides inducing pyroptosis, a type of inflammatory cell death [25]. This study aimed to evaluate the role of galanin in the modulation of the production of ROS and IL-1β secretion by granulocytes and PBMC, respectively, from MS patients.

Material and Methods

Ethical approval

The Ethical Committee from Santa Casa Hospital of Belo Horizonte-Brazil approved this study, and the informed consent was obtained from all participants included in the study.

Study population

Patients diagnosed with multiple sclerosis and healthy control, were selected by Dr. Paulo Pereira Christo, at the Neurology service of Santa Casa Hospital (Belo Horizonte, Minas Gerais, Brazil). Volunteers were within the age range of 18 and 65 years. Subjects presenting dementia, inflammation, infection or cancer were excluded from the study, as were pregnant women and individuals with alcohol or tobacco dependency.

Reagents

Human galanin compound was purchased from Merck (Merck KGaA, Darmstadt, Germany). For experiments, the concentration (2
μg/100 μL) was used according to previous studies performed by Agasse et al. [26].

Cell separation

Granulocytes and PBMNC were obtained from peripheral blood, according to Bicalho et al. [27], with slight modifications. Briefly heparinized peripheral venous blood samples (10 mL) were subjected to double-gradient density (1.08 and 1.12). The volume proportion among discontinuous gradient and blood were 4:3:3, respectively, from the bottom to the top using siliconized glass or Falcon tubes. After centrifugation during 30-40 min, layers at the top and middle interfaces were collected to yield fractions rich in PBMNC and granulocytes, respectively. The cells were identified and counted based on morphology, granulation and size using a stereoscopic microscope with 400X magnification. Cellular viability was evaluated by the Trypan Blue exclusion test.

Quantification of ROS production

A luminol-based chemiluminescence method was employed to assess the oxidative responses of granulocytes. An aliquot (200 μL) of of luminol (10⁻⁴ M) was mixed with a 100 μL of granulocytes suspension (1 × 10⁶/mL) in phosphate buffered saline (PBS). The chemiluminescence assay was performed on the Turner BioSystems model 20/20 n luminometer (Promega, Sunnyvale, CA, USA) for 20 min (control without stimulation), following which 100 μL of GAL (2000 nM) was added to the reaction mixture and chemiluminescence was performed for an additional 25 min.

Quantification of IL-1β in supernatant of cultured PBMNC

PBMNC (1 × 10⁵/100 μL) from MS patients and healthy controls in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) were incubated in the presence or absence of GAL (2 μM) for 72 h at 37°C under 5% CO₂. The final volume was adjusted to 300 μL in DMEM supplemented with 10% FBS. After incubation, the cells were centrifuged (200 g for 15 min) and the supernatant was collected. The interleukin-1β (human IL-1β-BioLegend, Inc., California, USA, cat. #437006) concentrations were determined through enzyme-linked immunosorbent assay (ELISA) according to the manufacturer instructions.

Statistical analysis

The Kolmogorov-Smirnov test was used to assess the normal distribution of the continuous variables; values were expressed as mean ± standard error. The Kolmogorov-Smirnov test was used to evaluate sample normality. Comparisons between groups were performed using unpaired Student t or the χ² test. All analyses were considered significant at values <0.05 using GraphPad Prism 5 (GraphPad Software, Inc).

Results

ROS production by granulocytes from MS patients increases in the presence of galanin

ROS production by granulocytes of MS patients and healthy controls in the presence or the absence of galanin are shown in Figures 1 and 2. The basal ROS production (absence of GAL) by granulocytes from MS patients and control group were similar (p>0.05). In the presence of GAL was observed an inhibition (26%) of ROS generation in cells from healthy control and activation (32%) in granulocytes from MS patients. The comparison was significant at p<0.05.

Galanin increases the secretion of IL-1β by PBMNC from MS patients and healthy controls

Figure 3 shows that Galanin activates IL-1β secretion similarly in both PBMNC from MS patients and healthy controls (p>0.05). The results, expressed as pg/mL (mean ± standard error), were 8.6 ± 2.0 and 9.7 ± 1.2 in the absence of GAL and 41.1 ± 13.0 and 39.9 ± 12.6 for healthy controls and MS patients, respectively. The results on IL-1β secretion in the absence and in the presence of GAL were significantly different at p<0.05.
Galanin activated production of ROS and the secretion of IL-1β in cells from patients with multiple sclerosis (Figures 1-3). The action of GAL depends on the interaction with the respective receptors (GALR1-3) [7,12,28,29] which are associated with G-protein coupled receptor (GPCR) family. Thus, GALR1 linked to the subunits of G-protein, Gi/o, is responsible for the inhibition of adenyl cyclase and activation of small GTPase (Ras). GALR2 is associated with G12/13 G-protein subunits and activates phospholipase C (PLC) leading to the formation of diacylglycerol (DAG) and inositoltiposphate (IP3). GALR3 inhibits adenyl cyclase, Rho, and Cdc42 by the Gi/o subunits. Several studies have shown that oxidative stress is an essential factor in the pathogenesis of demyelinating diseases [30-32]. Our results demonstrated that ROS production by granulocytes induced by galanin was significantly higher in cells from MS patients than that observed in healthy controls (p<0.05) (Figures 1 and 2). Sanadgol et al. [33] reported an active role for ROS in the pathogenesis of MS. Gruber et al. [34] demonstrated that increased ROS production interferes with myelin expression by oligodendrocytes. The ROS generation increases during the destruction of oligodendrocytes, astrocytes, and exacerbate the inflammatory process [33,35]. The present results may suggest that the action of galanin on granulocytes could involve mainly the activation of GALR2, PLC and consequently the signalling pathway DAG-PKC (protein kinase C)-NADPH-oxidase leading to the production of ROS. It is well known that inflammasome can be activated by ROS [36-39]. The production of pro-IL-1β by NF-kB in the presence of ROS promote inflammasome activation and secretion of IL-1β [36,40,41]. GAL induced the increase of secretion of IL-1β in cell culture supernatant of PBMNC from MS patients and control group (Figure 3). Studies have identified IL-1β and caspase-1 on sclerotic plaques, and increased levels of caspase-1 and IL-18 in PBMNC of MS patients [42,43]. Inoue et al. [44,45] demonstrated that the activation of NLRP3 in experimental MS model promotes the migration of inflammatory cells to the CNS. The inflammatory process induced by GAL appears to be complicated, and a possible network of several signalling pathways could be involved in the pathogenesis of MS. The understanding of these inflammatory mechanisms and the exact role of GAL in MS may offer subsidies to the identification of new therapeutic strategies.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Acknowledgement

The authors wish to thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à pesquisa do Estado de Minas Gerais (FAPEMIG) and Rede Mineira de Toxina Terapêutica 26/12 for their financial support. The funding bodies played no role in the study design, the data collection and analyzes, or the preparation/publication of the manuscript.

References

1. Hartung HP, Akitas O, Menge T, Kieseier BC (2014) Immune regulation of multiple sclerosis. Handb Clin Neurol 122: 3-14.
2. Hernandez-Pedro N, Magana-Maldonado R, Ramiro AS, Perez-De la Cruz V, Rangel-Lopez E, et al. (2016) PAMP-DAMP interactions mediates development and progression of multiple sclerosis. Front Biosci (Schol Ed) 8:13-28.
3. Hernandez-Pedro NY, Espinosa-Ramírez G, de la Cruz VP, Pineda B, Sotelo J (2013) Initial immunopathogenesis of multiple sclerosis: innate immune response. Clin Dev Immunol 2013: 413465.
4. Lyubetska H, Zhang L, Kong J, Vrontakis M (2015) An elevated level of circulating galanin promotes developmental expression of myelin basic protein in the mouse brain. Neuroscience 284: 581-589.
5. Wra Burlington DC, Pope R, Butakueven H, Holder H, Vanderplank P, et al. (2009) A role for galanin in human and experimental inflammatory demyelination. Proc Natl Acad Sci U S A 106: 15466-15471.
6. Kofler B, Berger A, Santic R, Moritz K, Almer D, et al. (2004) Expression of neuropeptide galanin and galanin receptors in human skin. J Invest Dermatol 122: 1050-1053.
7. Lang R, Kofler B (2011) The galanin peptide family in inflammation. Neuropeptides 45: 1-8.
8. Tatamoto K, Rokaeus A, Jornvall H, McDonald TJ, Matt V (1983) Galanin-a novel biologically active peptide from porcine intestine. FEBS lett 164: 124-128.
9. Fang P, Shi M, Zhu Y, Bo P, Zhang Z (2016) Type 2 diabetes mellitus as a disorder of galanin resistance. Exp Gerontol 70: 72-77.
10. Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick D, et al. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev 67: 118-175.
11. Lang R, Gundlach AL, Kofler B (2007) The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 115: 177-207.
12. Locker E, Lang AA, Kofler A, Lang R, Bianchini R, et al. (2015) Galanin modulates human and murine neutrophil activation in vitro. Acta physiologica 213: 595-602.
13. Bauer JW, Lang R, Jakab M, Kofler B (2008) Galanin family of peptides in skin function. Cell Mol Life Sci 65: 1820-1825.
14. Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, et al. (2009) Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 129: 2795-804.

Figure 3: Galanin (GAL) activates the production of IL-1β in mononuclear cells (PBMNC) of patients with multiple sclerosis and healthy control. Values expressed as mean ± standard error; analysis determined by student’s “t” test. *p<0.05 vs. PBMNC+DMEM. n=20 for each group.
15. Aydin O, Ellidag HY, Eren E, Kurtulus F, Yaman A, et al. (2014) Ischemia modified albumin is an indicator of oxidative stress in multiple sclerosis. Biochem Biophys Res Commun 450: 383-388.

16. Babior BM (1999) NADPH oxidase: an update. Blood 93: 1464-1476.

17. Fiorini A, Koudriavsteva T, Bucaj E, Coccia R, Foppoli C, et al. (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS one 8: e65184.

18. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274: 48-53.

19. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I (2012) Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 45: 26-30.

20. O'Sullivan SA, Velasco-Estevez M, Dev KK (2017) Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors. Glia 65: 1119-1136.

21. Veal EA, Day AM, Morgan BA (2007) Hydrogen peroxide sensing and signaling. Mol Cell 26: 1-14.

22. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, et al. (2006) IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 177: 5574-5584.

23. Ching S, Zhang H, Belevych N, He L, Lai W, et al. (2007) Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differenially alters CNS responses to IL-1 depending on its route of administration. J Neurosci 27: 10476-10486.

24. Akira S, Takeda K, Kaisho T (2001). Toll-like receptors: critical proteins as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm 2001: 425391.

25. Benetti E, Chiazza F, Patel NS, Collino M (2013) The NLRP3 Inflammasome as a novel player of the intercellular crosstalk in metabolic disorders. Mediators Inflamm 2013: 678627.

26. Agasse F, Kapelli S, Coronas V, Christiansen SH, Rosa AI, et al. (2013) Galanin promotes neuronal differentiation in murine subventricular zone cell cultures. Stem Cells Dev 22: 1693-1708.

27. Bicalho HM, Gontijo CM, Nogueira-Machado JA (1981). A simple technique for simultaneous human leukocytes separation. J Immunol Methods 40: 115-116.

28. Wozniak A, Betts WH, McLennan G, Scicchitano R (1993) Activation of human neutrophils by tachykinins: effect on formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-stimulated superoxide anion production and antibody-dependent cell-mediated cytotoxicity. Immunol Lett 78: 629-634.

29. Sipkova J, Kramarikova I, Hynie S, Klenerova V (2017) The galanin and galanin receptor subtypes, its regulatory role in the biological and pathological functions. Physiol Res 66: 729-740.

30. Goldberg I, Clarner T, Beyer C, Kipp M (2015) Anatomical Distribution of Cuprizone-Induced Lesions in C57BL6 Mice. J Mol Neurosci 57: 166-175.

31. Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, et al. (2009) Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol 29: 1370-1375.

32. Mirshafiey A, Mohsenzadegan M (2009) Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 31: 13-29.

33. Sanadgol N, Golab F, Askari H, Moradi F, Ajdry M, et al. (2018) Alpha-lipoic acid mitigates toxic-induced demyelination in the corpus callosum by lessening of oxidative stress and stimulation of polydendrocytes proliferation. Metabolic brain disease 33: 27-37.

34. Gruber RC, LaRocca D, Michenberg SB, Christophi GP, Hudson CA, et al. (2015) The control of reactive oxygen species production by SHP-1 in oligodendrocytes. Glia 63: 1753-1771.

35. Sanadgol N, Golab F, Mostafae A, Mehdizadeh M, Abdollahi M, et al. (2016) Ellagic acid ameliorates cuprizone-induced acute CNS inflammation via restriction of microgliosis and down-regulation of CCL2 and CCL3 pro-inflammatory chemokines. Cell Mol Biol (Noisy-le-grand) 62: 24-30.

36. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, et al. (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677.

37. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10: 241-247.

38. Harijith A, Ebenezer DL, Natarajan V (2014) Reactive oxygen species at reactive oxygen species at the crossroads of inflammasome and inflammation. Front Physiol 5: 352.

39. Schmidt RL, Lenz LL (2012) Distinct licensing of IL-18 and IL-1beta secretion in response to NLRP3 inflammasome activation. PLoS one 7: e45186.

40. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, et al. (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14: 1583-1589.

41. Picard C, Casanova JL, Puel A (2011) Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clinical microbiology reviews 24: 490-497.

42. Huang WX, Huang P, Hillert J (2004) Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler 10: 482-487.

43. Ming X, Li W, Maeda Y, Blumberg B, Raval S, et al. (2002) Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci 197: 9-18.

44. Inoue M, Williams KL, Gunn MD, Shinohara ML (2012) NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 109: 10480-10485.

45. Inoue M, Williams KL, Oliver T, Vandenaerde B, Rajan JV, et al. (2012) Interferon-beta therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Sci Signal 5: ra38.